Neutropenia resulting from high-dose intravenous immunoglobulin in dermatological patients.
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
06
04
2020
accepted:
29
06
2020
entrez:
29
12
2020
pubmed:
30
12
2020
medline:
19
8
2021
Statut:
ppublish
Résumé
Current guidelines recommend high-dose intravenous immunoglobulin (IVIG) as a rescue therapy to treat severe cutaneous autoimmune disorders. Data on IVIG-induced hematological adverse events are limited in dermatological patients. We assessed the incidence and clinical implications of IVIG-induced neutropenia. Patients who received one or several cycles of IVIG between 2014 and 2019 were retrospectively evaluated. IVIG was given according to standardized infusion protocols. Daily differential blood counts were performed. Information on clinical baseline data, dermatological diagnosis, immunosuppressive pre-treatment, and IVIG-related adverse events was retrieved from patient files. Seventeen patients received 106 IVIG treatment cycles. Neutrophil counts below 1,500/μL were documented during 36 (34.0 %) cycles, and neutrophils fell below 1,000/μL in 14 (13.2 %) cases. The average drop of neutrophils from day one (pre-dose) to days 2 and 3 of IVIG therapy was statistically significant (p = 0.006, and p = 0.002, respectively) despite correction for hemodilution, and so was a slight decrease of thrombocytes (p = 0.029, and p = 0.011, respectively). Four patients developed seven episodes of bacterial infections during or immediately after IVIG therapy. IVIG-induced neutropenia is frequent in dermatological patients. A risk of secondary bacterial infections cannot be excluded.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Current guidelines recommend high-dose intravenous immunoglobulin (IVIG) as a rescue therapy to treat severe cutaneous autoimmune disorders. Data on IVIG-induced hematological adverse events are limited in dermatological patients. We assessed the incidence and clinical implications of IVIG-induced neutropenia.
PATIENTS AND METHODS
METHODS
Patients who received one or several cycles of IVIG between 2014 and 2019 were retrospectively evaluated. IVIG was given according to standardized infusion protocols. Daily differential blood counts were performed. Information on clinical baseline data, dermatological diagnosis, immunosuppressive pre-treatment, and IVIG-related adverse events was retrieved from patient files.
RESULTS
RESULTS
Seventeen patients received 106 IVIG treatment cycles. Neutrophil counts below 1,500/μL were documented during 36 (34.0 %) cycles, and neutrophils fell below 1,000/μL in 14 (13.2 %) cases. The average drop of neutrophils from day one (pre-dose) to days 2 and 3 of IVIG therapy was statistically significant (p = 0.006, and p = 0.002, respectively) despite correction for hemodilution, and so was a slight decrease of thrombocytes (p = 0.029, and p = 0.011, respectively). Four patients developed seven episodes of bacterial infections during or immediately after IVIG therapy.
CONCLUSIONS
CONCLUSIONS
IVIG-induced neutropenia is frequent in dermatological patients. A risk of secondary bacterial infections cannot be excluded.
Substances chimiques
Immunoglobulins, Intravenous
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1394-1403Informations de copyright
© 2020 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
Komatsu-Fujii T, Honda T, Tahara J et al. Efficacy of intravenous immunoglobulins for laryngopharyngeal lesions and upper airway obstruction in epidermolysis bullosa acquisita. J Eur Acad Dermatol Venereol 2020; 34: e131-e3.
Blanchard SK, Sullivan KM, Hooten JN et al. High-dose intravenous immunoglobulin as adjuvant treatment for grade IV acute cutaneous graft-versus-host disease. Br J Dermatol 2019; 181: 869-71.
Micheletti RG, Chiesa-Fuxench Z, Noe MH et al. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A multicenter retrospective study of 377 adult patients from the United States. J Invest Dermatol 2018; 138: 2315-21.
Song H, Lahood N, Mostaghimi A. Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series. Br J Dermatol 2018; 178: 363-8.
Galimberti F, Kooistra L, Li Y et al. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis. Clin Exp Dermatol 2018; 43: 906-12.
Amagai M, Ikeda S, Hashimoto T et al. A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. J Dermatol Sci 2017; 85: 77-84.
Amagai M, Ikeda S, Shimizu H et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009; 60: 595-603.
Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000.
Enk A, Hadaschik E, Eming R et al. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. J Dtsch Dermatol Ges 2017; 15: 228-41.
Schmidt E, Sticherling M, Sárdy M et al. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update. J Dtsch Dermatol Ges 2020; 18: 516-26.
Hoffmann JHO, Enk AH. High-dose intravenous immunoglobulin in skin autoimmune disease. Front Immunol 2019; 10: 1090.
Harman KE, Brown D, Exton LS et al. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol 2017; 177: 1170-201.
Hoffmann JHO, Enk AH. High-dose intravenous immunoglobulins for the treatment of dermatological autoimmune diseases. J Dtsch Dermatol Ges 2017; 15: 1211-26.
Hertl M, Jedlickova H, Karpati S et al. Pemphigus. S2 Guideline for diagnosis and treatment-guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2015; 29: 405-14.
Späth PJ, Granata G, La Marra F et al. On the dark side of therapies with immunoglobulin concentrates: the adverse events. Front Immunol 2015; 6: 11.
Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013; 27: 171-8.
Center for Disease Control and Prevention C. Renal insufficiency and failure associated with immune globulin intravenous therapy-United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999; 48: 518-21.
Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 1986; 314: 560-4.
Scribner CL, Kapit RM, Phillips ET et al. Aseptic meningitis and intravenous immunoglobulin therapy. Ann Intern Med 1994; 121: 305-6.
Wang Z, Weng F, Li C et al. Neutropenia after intravenous immunoglobulin therapy is associated with coronary artery lesions in children with Kawasaki disease: a case control study. BMC Pediatr 2018; 18: 76.
Niebanck AE, Kwiatkowski JL, Raffini LJ. Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia. J Pediatr Hematol Oncol 2005; 27: 145-7.
Sugita K, Eguchi M. Suppressive effect of intravenous immunoglobulin on peripheral blood neutrophil count in patients with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2005; 27: 7-10.
Singh A, Arif F, Smith SD. Intravenous immunoglobulin-induced reversible neutropenia in a renal transplant patient. Clin Nephrol 2005; 64: 246-8.
Matsuda M, Hosoda W, Sekijima Y et al. Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders. Clin Neuropharmacol 2003; 26: 306-11.
Berkovitch M, Dolinski G, Tauber T et al. Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming. Int J Immunopharmacol 1999; 21: 411-5.
Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve 1997; 20: 1102-7.
Lassiter HA, Bibb KW, Bertolone SJ et al. Neonatal immune neutropenia following the administration of intravenous immune globulin. Am J Pediatr Hematol Oncol 1993; 15: 120-3.
Majer RV, Green PJ. Neutropenia caused by intravenous immunoglobulin. Br Med J (Clin Res Ed) 1988; 296: 1262.
Veys PA, Macey MG, Owens CM et al. Neutropenia following intravenous immunoglobulin. Br Med J (Clin Res Ed) 1988; 296: 1800.
Cicha A, Fischer MB, Wesinger A et al. Effect of intravenous immunoglobulin administration on erythrocyte and leucocyte parameters. J Eur Acad Dermatol Venereol 2018; 32: 1004-10.
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11pdf [Last accessed on June 23, 2020].
Blaser L, Hassna H, Hofmann S et al. Leucopenia associated with metamizole: a case-control study. Swiss Med Wkly 2017; 147: w14438.
Parodis I, Söder F, Faustini F et al. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL. Lupus 2018; 27: 1470-8.
Altznauer F, von Gunten S, Späth P et al. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol 2003; 112: 1185-90.
vonGunten S, Schaub A, Vogel M et al. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 2006; 108: 4255-9.
Getta B, Ponniah G, Ling S. Intravenous immunoglobulin induces short-term reversal of drug-induced autoimmune neutropenia. Transfus Med 2015; 25: 347-8.
Desenfants A, Jeziorski E, Plan O et al. Intravenous immunoglobulins for neonatal alloimmune neutropenia refractory to recombinant human granulocyte colony-stimulating factor. Am J Perinatol 2011; 28: 461-6.
Ronchetti S, Ricci E, Migliorati G et al. How glucocorticoids affect the neutrophil life. Int J Mol Sci. 2018; 19.
Baxley A, Akhtari M. Hematologic toxicities associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2011; 11: 1663-7.
Bellac CL, Hottiger T, Jutzi MP et al. The role of isoagglutinins in intravenous immunoglobulin-related hemolysis. Transfusion 2015; 55 (Suppl 2): S13-22.
Daw Z, Padmore R, Neurath D et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008; 48: 1598-601.